WaveMan
WaveMan · Company
EDIT · Editas Medicine, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

EDIT Editas Medicine (EDIT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001650664
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
111
13F, latest reported quarter

What the filings say about EDIT

Insiders, 180 days
-$78.8K net sold
3 sellers · 38% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$19.0K
2 notices

Editas Medicine insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Editas Medicine, Inc. insiders sold a net $78.8K of stock across 77 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
O'Neill Gilmore Neil
CEO
SELL
2026-09-04 SECtraded 2026-09-03
5,124
$15.6K
-20.8%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jun 3, 2026.
  • The trade is 2.1% of the 243,189 shares held after it.
  • 2 other insiders sold within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO O'Neill Gilmore Neil sold about $15.6K of EDIT under a 10b5-1 plan on Sep 3, 2026; 2 other insiders sold within 30 days and 111 funds added in the latest 13F quarter.
Parison Amy
SVP, Chief Financial Officer
SELL
2026-09-04 SECtraded 2026-09-03
453
$1.4K
-20.8%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Aug 3, 2026.
  • The trade is 3.3% of the 13,839 shares held after it.
  • 2 other insiders sold within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Financial Officer Parison Amy sold about $1.4K of EDIT under a 10b5-1 plan on Sep 3, 2026; 2 other insiders sold within 30 days and 111 funds added in the latest 13F quarter.
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
SELL
2026-09-04 SECtraded 2026-09-03
709
$2.2K
-20.8%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Jul 28, 2026.
  • The trade is 1.1% of the 61,660 shares held after it.
  • 2 other insiders sold within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda sold about $2.2K of EDIT under a 10b5-1 plan on Sep 3, 2026; 2 other insiders sold within 30 days and 111 funds added in the latest 13F quarter.
Parison Amy
SVP, Chief Financial Officer
SELL
2026-08-05 SECtraded 2026-08-03
678
$1.7K
-17.2%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 3, 2026.
  • The trade is 4.7% of the 14,292 shares held after it.
  • 1 other insider sold within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Chief Financial Officer Parison Amy sold about $1.7K of EDIT on Aug 3, 2026; 1 other insider sold within 30 days and 111 funds added in the latest 13F quarter.
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
SELL
2026-07-29 SECtraded 2026-07-28
4,928
$13.2K
-10.8%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Jun 3, 2026.
  • The trade is 7.9% of the 62,369 shares held after it.
  • 1 other insider sold within 30 days.
  • 111 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda sold about $13.2K of EDIT on Jul 28, 2026; 1 other insider sold within 30 days and 111 funds added in the latest 13F quarter.
77 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 72 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$78.8K over 180 days
-$20.8K over 90 days
more than 56% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
111 funds bought in last quarter
more than 72% of Pharma & Biotech
Revenue
+25.4% year over year
more than 70% of Pharma & Biotech
Margin
-395.0% net margin
below 75% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
32.1% of the float short (float per yahoo 2026-10-26) · 9.3 days to cover · settled 2026-09-30
more than 98% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch EDIT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-34.2%12M
-54%-35%-16%+3%2025-102025-122026-022026-042026-062026-082026-10 2026-06-03 · O'Neill Gilmore Neil sold $41.5K2026-09-03 · O'Neill Gilmore Neil sold $15.6K2026-07-28 · Burkly Linda sold $13.2K2025-12-03 · O'Neill Gilmore Neil sold $12.0K2026-03-03 · O'Neill Gilmore Neil sold $10.9K2026-09-03 · Burkly Linda sold $2.2K2026-06-03 · Burkly Linda sold $2.0K2026-08-03 · Parison Amy sold $1.7K2025-12-03 · Burkly Linda sold $1.5K2026-03-03 · Burkly Linda sold $1.5K2026-09-03 · Parison Amy sold $1.4K2026-06-03 · Parison Amy sold $1.3K2025-12-03 · Parison Amy sold $9912026-03-03 · Parison Amy sold $9572026-08-31 · Burkly Linda filed to sell $2.3K2026-08-31 · O'Neill Gilmore Neil filed to sell $16.7K2026-07-21 · Burkly Linda filed to sell $15.8K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns EDIT: institutional holders (13F)

13F holdings, latest reported quarter
TCG Crossover Management, LLC
11,111,111 sh
$36.0M
BlackRock, Inc.
10,589,990 sh
$34.3M
RA CAPITAL MANAGEMENT, L.P.
8,889,000 sh
$28.8M
Commodore Capital LP
8,889,000 sh
$28.8M
ADAR1 Capital Management, LLC
8,889,000 sh
$28.8M

Congress trades in EDIT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

EDIT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Burkly Linda
Filed 2026-08-31
$2.3K
O'Neill Gilmore Neil
Filed 2026-08-31
$16.7K
Burkly Linda
Filed 2026-07-21
$15.8K

EDIT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco NASDAQ Future Gen 200 ETF
$121.5K position · as of 2026-05-31
0.6%
Horizon Kinetics Medical ETF
$89.7K position · as of 2026-06-30
0.5%
AXS Green Alpha ETF
$198.3K position · as of 2026-06-30
0.3%
Global X Genomics & Biotechnology ETF
$189.3K position · as of 2026-05-31
0.3%
Ultra-Small Company Market Fund
$408.2K position · as of 2026-06-30
0.3%
Small Company Growth Portfolio
$38.7K position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Not applicable
1 active
3
Multi-phase
3 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $78.8K sold by insiders over 180 days, 111 funds added last quarter, $19.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

EDIT financials

Revenue growth
+25.4%
XBRL, annual
Net margin
-395.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$47.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-157.3%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$120.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.53x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-2.15x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-118.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-33.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-48.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$242.5M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-32.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$40.5M$32.3M$78.1M$19.7M
Operating income-$160.0M-$251.2M-$169.2M-$225.9M
Net income-$160.1M-$237.1M-$153.2M-$220.4M
EPS (diluted)-1.80-2.88-2.02-3.21
Operating cash flow-$165.2M-$210.3M-$132.2M-$177.3M
Cash$146.6M$131.5M$123.7M$141.5M
Long-term debt$53.6M$52.4M$0n/a
SEC XBRL, fiscal years, as known on 2026-10-28

EDIT Stock Sonar score 6/7 axes

Find similar shapesCompare

EDIT ranks highest on institutional and government (72nd percentile) and growth (70th), and lowest on risk and compliance (23rd), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
46
Inputs
  • Return on equity-118.8% · 29 pct, sector of 545
  • Return on assets-33.0% · 57 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-48.4% · 52 pct, sector of 576
Financial health
37
Inputs
  • Debt to equity0.53x · 30 pct, sector of 352
  • Cash flow to debt-2.15x · 43 pct, sector of 371
Growth
70
Inputs
  • Revenue growth, YoY+25.4% · 70 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
28
Inputs
  • Net Form 4 buying (codes P and S), 180d-$60K · 55 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
72
Inputs
  • Funds adding, latest quarter111 · 72 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
23
Inputs
  • Short interest, % of float+32.1% · 3 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+11.8% · 44 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

EDIT filings, in plain words

Are Editas Medicine insiders buying or selling EDIT?

In the 180 days to 2026-10-28, Editas Medicine insiders were net sellers, a net $78.8K across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of EDIT?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $19.0K of stock; the latest, by Burkly Linda, was filed 2026-08-31.

Read the full summary

In the 180 days to 2026-10-28, Editas Medicine insiders were net sellers of EDIT, a net $78.8K across purchases and sales reported on Form 4 by 3 sellers. 38% of the 8 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $19.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies